Serum Iron Markers in Patients WithChronic Hepatitis C Infection

Vagu, Codruţa; Sultana, Camelia; Ruţă, Simona

doi:10.5812/hepatmon.13136

Cited by 16 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, iron accumulation in HBV and HCV infections [33] causes liver damage due to oxidative stress, which increases hepatocyte necrosis/apoptosis, hepatic stellate cell activation and fibrogenesis through the proliferation of actin and collagen [34] , [35] . However, iron markers do not differ significantly in patients with low or high HCV viremia [36] . Serum ferritin and transferrin levels appear to play an important role in determining the severity of liver disease related both to liver fibrosis and necroinflammatory activity but not the presence of infection.…”

Section: Resultsmentioning

confidence: 84%

Comparative Salivary Proteome of Hepatitis B- and C-Infected Patients

et al. 2014

View full text Add to dashboard Cite

Hepatitis B and C virus (HBV and HCV) infections are an important cause of cirrhosis and hepatocellular carcinoma. The natural history has a prominent latent phase, and infected patients may remain undiagnosed; this situation may lead to the continuing spread of these infections in the community. Compelling reasons exist for using saliva as a diagnostic fluid because it meets the demands of being an inexpensive, noninvasive and easy-to-use diagnostic method. Indeed, comparative analysis of the salivary proteome using mass spectrometry is a promising new strategy for identifying biomarkers. Our goal is to apply an Orbitrap-based quantitative approach to explore the salivary proteome profile in HBV- and HCV-infected patients. In the present study, whole saliva was obtained from 20 healthy, (control) 20 HBV-infected and 20 HCV-infected subjects. Two distinct pools containing saliva from 10 subjects of each group were obtained. The samples were ultracentrifuged and fractionated, and all fractions were hydrolyzed (trypsin) and injected into an LTQ-VELOS ORBITRAP. The identification and analyses of peptides were performed using Proteome Discoverer1.3 and ScaffoldQ + v.3.3.1. From a total of 362 distinct proteins identified, 344 proteins were identified in the HBV, 326 in the HCV and 303 in the control groups. Some blood proteins, such as flavin reductase (which converts biliverdin to bilirubin), were detected only in the HCV group. The data showed a reduced presence of complement C3, ceruloplasmin, alpha(1)-acid glycoprotein and alpha(2)-acid glycoprotein in the hepatitis-infected patients. Peptides of serotransferrin and haptoglobin were less detected in the HCV group. This study provides an integrated perspective of the salivary proteome, which should be further explored in future studies targeting specific disease markers for HBV and HCV infection.

show abstract

Section: Resultsmentioning

confidence: 84%

Comparative Salivary Proteome of Hepatitis B- and C-Infected Patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Many previous studies suggested excessive iron accumulation in the hepatocyte accelerate hepatocellular damage, liver fibrosis, and eventually increase risk of hepatocellular carcinoma. 18 , 19 There were several studies to determine regulatory system of iron metabolism to maintain homeostasis and some studies proposed transferrin and hepcidin, which play a crucial role in iron metabolism, as surrogate markers for predicting severity of liver disease in the patients with chronic hepatitis C. 20 , 21 Recently, Xu et al performed proteomic study to identify reliable non-invasive serum biomarkers of liver fibrosis in patients with CHB, and they reported decreased level of serum transferrin in cirrhotic patients compared with non-cirrhotic patients. 22 But there was no other study which validated serum transferrin as liver fibrosis marker in patients with CHB.…”

Section: Introductionmentioning

confidence: 99%

Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B

et al. 2014

View full text Add to dashboard Cite

Background/AimsTransferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B.MethodsThe study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared.ResultsUnivariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B.ConclusionsSerum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.

show abstract

“…The prevalence of HCV is estimated to be 3% worldwide; out of which, approximately 170 billion people are affected with the hepatitis C antibody. 1,2 Around 20% of chronic hepatitis C (CHC) cases progressed to cirrhosis that is a life-threatening hepatic condition. 2 Other risk factors associated with CHC are decompensated liver disease and hepato-cellular carcinoma, which ultimately requires liver transplantation.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 Around 20% of chronic hepatitis C (CHC) cases progressed to cirrhosis that is a life-threatening hepatic condition. 2 Other risk factors associated with CHC are decompensated liver disease and hepato-cellular carcinoma, which ultimately requires liver transplantation. Different viral factors (such as genotype and baseline viral load), comorbidities, and genetic background of the host characterize the outcomes of HCV infection.…”

Section: Introductionmentioning

confidence: 99%

“…The positive association between increased concentration of serum iron markers (such as iron, ferritin, and transferrin) and accumulation of iron in liver among patients, suffering from CHC, have been reported by few studies. 2,4,5 However, the diagnosis of cirrhosis in CHC is significant because liver fibrosis at stage III and IV is mostly observed. Therefore, there is a higher risk of liver decompensation among the patients, suffering from advanced liver fibrosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating Responsiveness of Raised Serum Ferritin for Treatment in Patients with Chronic Hepatitis C Infection

Aziz

2019

J. Medicine

View full text Add to dashboard Cite

Background: Hepatitis C virus infection (HCV) is known as a major public health challenge across the world. There is a positive association between iron accumulation in hepatocytes and increased concentration of serum markers, including ferritin and transferrin. The study has aimed to investigate the responsiveness of increased serum ferritin levels among patients suffering HCV infection. Materials and Methods: The study has recruited 195 patients from the Hamad General Hospital, who were suffering with HCV infection. The clinical characteristics included HCV viral load, biochemical data, and parameters of iron status were evaluated among all the patients. The obtained results were quantitatively analyzed using Microsoft excel 2013. Results: The results revealed that the correlation between HCV and iron accumulation in hepatocytes is significantly interfered by the anti-viral treatment. The mean value of iron for positive PCR was calculated to be 19.93 μmol/L; and for negative PCR, the value was estimated to be 24.61 μmol/L before administration of drug. The iron level was 62.77 μmol/L among the patients with positive PCR, which is within normal range. The decrease in level of ferritin represents negative results after the drug administration. Increased levels of ALT were observed among 37.62 percent of the patients. Conclusions: The patients, suffering from chronic HCV, possess significant association with serum iron levels. J MEDICINE JAN 2020; 21 (1) : 14-19

show abstract

Serum Iron Markers in Patients WithChronic Hepatitis C Infection

Cited by 16 publications

References 20 publications

Comparative Salivary Proteome of Hepatitis B- and C-Infected Patients

Comparative Salivary Proteome of Hepatitis B- and C-Infected Patients

Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B

Evaluating Responsiveness of Raised Serum Ferritin for Treatment in Patients with Chronic Hepatitis C Infection

Contact Info

Product

Resources

About